-
2024-511465-11-00
5
2024-11-20
Spontaneous lobar ICH
-
2023-507482-26-00
5
2024-10-04
Castrate-resistant prostate cancer with oligometastases on functional
-
2024-513087-26-00
5
2024-09-10
Metastatic Non-small Cell Lung Cancer
-
2024-511959-18-01
5
2024-07-01
Acute Pulmonary Embolism
-
2023-505871-63-00
5
2024-04-08
ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 in
-
2023-503412-33-00
5
2024-03-29
Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small cell lung cance
-
2023-504323-25-01
5
2024-03-19
breast cancer
-
2023-505385-28-00
4
2023-10-19
male or pre/post-menopausal women age ≥ 18 years with locally advanced
-
2023-503373-37-01
4
2023-09-11
Premenopausal women with early luminal breast cancer
-
2023-504999-25-00
5
2023-07-14
Acute Myeloid Leukemia
-
2024-512726-28-00
6
2022-02-14
peritoneal metastases of colorectal cancer
-
2024-512953-26-00
5
2021-07-06
intermediate-stage hepatocellular carcinoma
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2022-502706-33-00
6
2018-01-10
Patients with invasive breast cancer in early stages
-
2024-516609-22-00
5
2025-04-15
Primary Sjögren’s Disease
-
2024-512676-36-00
10
2024-10-09
Langerhans Cell Histiocytosis
-
2023-508670-28-00
5
2024-08-26
Hypertension
-
2024-514525-34-00
5
2024-08-18
Aetiological treatment of moderate-severe intermitent or persistent al
-
2022-502442-27-00
5
2024-01-08
Obesity
-
2023-503265-27-00
5
2023-11-23
Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Co
-
2024-515047-31-00
5
2023-08-28
Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) at stage
-
2022-501024-20-00
5
2023-07-25
ER+/HER2- Early Breast Cancer
-
2022-502145-10-00
5
2023-06-06
Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor
-
2024-511169-12-00
5
2023-03-28
Non-Small Cell Lung Cancer